Cargando…

Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d

iNKT cells are CD1d-restricted T cells recognizing lipid antigens. The prototypic iNKT cell-agonist α-galactosylceramide (α-GalCer) alongside compounds with similar structures induces robust proliferation and cytokine production of iNKT cells and protects against cancer in vivo. Monoclonal antibodie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clark, Katharine, Yau, Jessica, Bloom, Anja, Wang, Jing, Venzon, David J., Suzuki, Motoshi, Pasquet, Lise, Compton, Benjamin J., Cardell, Susanna L., Porcelli, Steven A., Painter, Gavin F., Zajonc, Dirk M., Berzofsky, Jay A., Terabe, Masaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794452/ https://www.ncbi.nlm.nih.gov/pubmed/31649670 http://dx.doi.org/10.3389/fimmu.2019.02355

Ejemplares similares

CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

Structure and binding kinetics of three different human CD1d–α-galactosylceramide–specific T cell receptors
por: Gadola, Stephan D., et al.
Publicado: (2006)

Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

CD1d-mediated Recognition of an α-Galactosylceramide by Natural Killer T Cells Is Highly Conserved through Mammalian Evolution
por: Brossay, Laurent, et al.
Publicado: (1998)

Liver sulfatide-reactive type II NKT cells recognize endogenous phospholipids
por: Kato, Shingo, et al.
Publicado: (2014)

Defective NKT Cell Activation by CD1d+ TRAMP Prostate Tumor Cells Is Corrected by Interleukin-12 with alpha-Galactosylceramide
por: Nowak, Michael, et al.
Publicado: (2010)

The Molecular Basis for Recognition of CD1d/α-Galactosylceramide by a Human Non-Vα24 T Cell Receptor
por: López-Sagaseta, Jacinto, et al.
Publicado: (2012)

Type II NKT cells differentially regulate CD4 T cell subsets
por: Robertson, Faith C, et al.
Publicado: (2014)

The Vα14 invariant natural killer T cell TCR forces microbial glycolipids and CD1d into a conserved binding mode
por: Li, Yali, et al.
Publicado: (2010)

Requirements for CD1d Recognition by Human Invariant Vα24(+) CD4(−)CD8(−) T Cells
por: Exley, Mark, et al.
Publicado: (1997)

Glycolipid-peptide conjugate vaccines enhance CD8(+) T cell responses against human viral proteins
por: Speir, M., et al.
Publicado: (2017)

Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses
por: Zhang, Lianjun, et al.
Publicado: (2017)

A nonclassical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance
por: Terabe, Masaki, et al.
Publicado: (2005)

Norovirus GII.4 Virus-like Particles Recognize Galactosylceramides in Domains of Planar Supported Lipid Bilayers**
por: Bally, Marta, et al.
Publicado: (2012)

Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer
por: Wang, Ying, et al.
Publicado: (2020)

Liposomal Nanovaccine Containing α-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8(+) T Cell Responses via CD169(+) Macrophages and cDC1
por: Grabowska, Joanna, et al.
Publicado: (2021)

Species Specific Differences of CD1d Oligomer Loading In Vitro
por: Paletta, Daniel, et al.
Publicado: (2015)

Invariant NKT cells limit activation of autoreactive CD1d-positive B cells
por: Wermeling, Fredrik, et al.
Publicado: (2010)

CD1d-restricted Recognition of Synthetic Glycolipid Antigens by Human Natural Killer T Cells
por: Spada, Franca M., et al.
Publicado: (1998)

Galactosylsphingamides: new α-GalCer analogues to probe the F’-pocket of CD1d
por: Guillaume, Joren, et al.
Publicado: (2017)

Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity
por: Zajonc, Dirk M., et al.
Publicado: (2005)

Distinct Subsets of CD1d-restricted T Cells Recognize Self-antigens Loaded in Different Cellular Compartments
por: Chiu, Ya-Hui, et al.
Publicado: (1999)

Prevention of Autoimmunity by Targeting a Distinct, Noninvariant CD1d-reactive T Cell Population Reactive to Sulfatide
por: Jahng, Alex, et al.
Publicado: (2004)

Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d‐independent manner
por: Aoki, Takahiro, et al.
Publicado: (2020)

INT230-6 shows strong synergy with anti-PD-1 and can induce high complete response rates with T cell memory response in a colon cancer mouse model
por: Bloom, Anja C, et al.
Publicado: (2015)

Transforming Growth Factor-β Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte–mediated Tumor Immunosurveillance: Abrogation Prevents Tumor Recurrence
por: Terabe, Masaki, et al.
Publicado: (2003)

Tissue-Specific Roles of NKT Cells in Tumor Immunity
por: Terabe, Masaki, et al.
Publicado: (2018)

KLF13 sustains thymic memory-like CD8(+) T cells in BALB/c mice by regulating IL-4–generating invariant natural killer T cells
por: Lai, Dazhi, et al.
Publicado: (2011)

Alpha-galactosylceramide enhances protective immunity induced by DNA vaccine of the SAG5D gene of Toxoplasma gondii
por: Lu, Gang, et al.
Publicado: (2014)

Mouse and Human CD1d-Self-Lipid Complexes Are Recognized Differently by Murine Invariant Natural Killer T Cell Receptors
por: Guo, Tingxi, et al.
Publicado: (2016)

Defining a novel subset of CD1d‐dependent type II natural killer T cells using natural killer cell‐associated markers
por: Singh, Avadhesh Kumar, et al.
Publicado: (2019)

B7-H1-Deficiency Enhances the Potential of Tolerogenic Dendritic Cells by Activating CD1d-Restricted Type II NKT Cells
por: Brandl, Carolin, et al.
Publicado: (2010)

The PGRMC1 Antagonist AG-205 Inhibits Synthesis of Galactosylceramide and Sulfatide
por: Wang-Eckhardt, Lihua, et al.
Publicado: (2021)

CD161 (NKR-P1A) Costimulation of CD1d-dependent Activation of Human T Cells Expressing Invariant Vα24JαQ T Cell Receptor α Chains
por: Exley, Mark, et al.
Publicado: (1998)

Crystal Structures of Bovine CD1d Reveal Altered αGalCer Presentation and a Restricted A’ Pocket Unable to Bind Long-Chain Glycolipids
por: Wang, Jing, et al.
Publicado: (2012)

Overcoming CD4 deficiency to induce long-lived memory CD8(+ )CTL
por: Oh, SangKon, et al.
Publicado: (2006)

Identification and Characterization of Circulating Naïve CD4+ and CD8+ T Cells Recognizing Nickel
por: Bechara, Rami, et al.
Publicado: (2019)

New CD1d agonists: Synthesis and biological activity of 6″-triazole-substituted α-galactosyl ceramides
por: Jervis, Peter J., et al.
Publicado: (2012)

Balance is a key for happiness
por: Izhak, Liat, et al.
Publicado: (2013)

Possible Therapeutic Application of Targeting Type II Natural Killer T Cell-Mediated Suppression of Tumor Immunity
por: Kato, Shingo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1ofj01s6m0esp3j83k9c4v192i